| __timestamp | Bristol-Myers Squibb Company | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 22570000 |
| Thursday, January 1, 2015 | 5001000000 | 24378000 |
| Friday, January 1, 2016 | 5002000000 | 26621000 |
| Sunday, January 1, 2017 | 4849000000 | 28653000 |
| Monday, January 1, 2018 | 4551000000 | 37734000 |
| Tuesday, January 1, 2019 | 4871000000 | 41884000 |
| Wednesday, January 1, 2020 | 7661000000 | 64435000 |
| Friday, January 1, 2021 | 7690000000 | 57483000 |
| Saturday, January 1, 2022 | 7814000000 | 70062000 |
| Sunday, January 1, 2023 | 7772000000 | 52790000 |
| Monday, January 1, 2024 | 8414000000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and Ligand Pharmaceuticals Incorporated from 2014 to 2023.
Bristol-Myers Squibb, a giant in the industry, has seen its SG&A expenses fluctuate over the years. Notably, 2020 marked a significant increase, with expenses peaking at approximately $7.7 billion, a 70% rise from 2018. This surge reflects strategic investments and expansions.
In contrast, Ligand Pharmaceuticals, a smaller player, maintained a more stable SG&A expense profile. Despite a steady increase, their expenses in 2023 were around $52.8 million, highlighting a leaner operational model.
This comparison underscores the diverse strategies within the pharmaceutical sector, where scale and efficiency play pivotal roles in shaping financial outcomes.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Bristol-Myers Squibb Company and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Merus N.V. vs Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Galapagos NV